8th Annual CAR-TCR Summit Europe
The 8th CAR-TCR Summit Europe returns to London this February as your must-attend forum to remain on the pulse of recent innovation in cell therapy. Join us to collaborate, innovate, and overcome the shared challenges of safety concerns, high cost of goods, effective tumour targeting, and more. Let’s work together to drive success in clinical trials, secure regulatory approvals, and position cell therapy as the first-line treatment for oncological and non-oncological indications.
Date: February 25-27, 2025
Location: London, UK
Booth: TBD
JOIN US!
Catalent can accelerate your cell therapy program to the clinic. Our expertise covers all areas of cell therapy including iPS cell lines & differentiation, autologous & allogeneic therapies, plasmid DNA, viral vectors, process development, integrated & standalone analytical services and clinical & commercial manufacturing. Meet our experts to learn more about these integrated offerings
Complete the form to schedule a meeting with Catalent at the 8th Annual CAR-TCR Summit Europe.
WORKSHOP PRESENTATION
Title: De-risking the Journey From Bench to Patient
Date: February 26, 2025
Time: 2:30 pm
- Comprehensive, science-based solutions for cell therapy programs
- A flexible approach to accelerate the path to clinic and de-risk the manufacturing process
- From concept to market- off the shelf solutions with full journey support
SPEAKER
Nuria Gomez Santos, Ph.D
Director Process and Analytical Development
Catalent Cell and Gene Therapy
ABOUT CATALENT CELL & GENE THERAPY
Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vectors, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. An experienced and innovative partner, Catalent Cell & Gene Therapy has a global network of dedicated development, clinical and commercial manufacturing facilities for small- and large-scale programs.
